Massachusetts insurers eliminate GLP-1 weight loss drug coverage due to soaring costs
Beginning in 2026, Massachusetts insurance companies including Blue Cross Blue Shield, MassHealth, and the Group Insurance Commission stopped covering GLP-1 weight loss medications like Wegovy and Zepbound due to skyrocketing costs. Insurance leaders say these drugs grew unsustainably, with spending doubling nearly every year. Private insurers spent over a billion dollars on them in 2025. The change affected more than 112,000 commercially insured members in the first quarter of 2026 alone—a 52 percent decline in coverage from 2025. The drugs remain covered when prescribed for diabetes and some other medical conditions. State officials acknowledge the policy restricts access for lower-income patients who can't afford out-of-pocket costs, which exceed 1,300 dollars monthly. Meanwhile, doctors and patients argue obesity is a chronic disease deserving treatment, and some warn the savings may prove short-lived if untreated obesity leads to costlier health problems down the road.
Key facts
- Blue Cross Blue Shield of Massachusetts ended GLP-1 weight loss coverage starting January 1, 2026, affecting tens of thousands of members.
- MassHealth discontinued GLP-1 weight loss coverage effective July 1, 2026, affecting approximately 22,000 low-income state residents.
- Commercial insurance spending on GLP-1 drugs for weight loss fell from nearly 1 billion dollars in 2025 to approximately 662 million dollars in 2026.
- Between Q4 2025 and Q1 2026, 112,000 fewer commercially insured Massachusetts residents had GLP-1 weight loss coverage—a 52 percent decline.
- GLP-1 spending for weight loss had grown at an average annual rate of 99.5 percent from 2019 to 2025 before insurers halted coverage.
- Monthly costs for GLP-1 medications like Wegovy range from approximately 950 to 1,350 dollars before insurance.
- GLP-1 medications remain covered when prescribed for type 2 diabetes and certain other FDA-approved conditions like cardiovascular disease.
How different outlets framed it
Left-leaning coverage: Progressive advocates and unions frame this as an unjust denial of effective healthcare, arguing obesity is a chronic disease deserving equal treatment to diabetes and other conditions. They emphasize equity concerns, noting that lower-income MassHealth members cannot afford high out-of-pocket costs, and they question whether short-term budget savings will actually cost more long-term through obesity-related complications. Labor unions like the Massachusetts Teachers Association called for negotiating better drug pricing rather than eliminating coverage outright.
Limits of this briefing
Right-leaning news outlets did not prominently cover this story with distinct framing in available sources; the dominant perspectives found were left-leaning advocacy and centrist/mainstream journalism. The long-term health and economic outcomes of eliminating coverage remain unresolved and will depend on future drug pricing and patient health trajectories.
Sources
- WBUR News: With Mass. cutting weight loss drug coverage, patients scramble to afford prescriptions Centre
- Massachusetts Teachers Association: GIC Insurance: The Ongoing Fight for GLP-1 Coverage Left
- The Boston Globe: Private health insurers covered 112,000 fewer Mass. residents' GLP-1 weight-loss drugs this year, report finds Centre
- Massachusetts Health Policy Commission: GLP-1 Spending in Massachusetts Projected To Decrease Significantly in 2026 After Changes in Commercial Coverage Centre
- Obesity Action Coalition: Why Massachusetts Must Protect Access to GLP-1 Medications for State Employees Left